New drug combo aims to reboot immune attack in Hard-to-Treat cancers
NCT ID NCT07219576
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 25 times
Summary
This study tests a new combination of two drugs (retifanlimab and ruxolitinib) in people with advanced lung or kidney cancer whose tumors grew despite prior immunotherapy. The main goal is to find the safest dose of ruxolitinib when given with a fixed dose of retifanlimab, and to see if the combination can shrink tumors. About 40 participants will take ruxolitinib pills at home and receive retifanlimab infusions every 4 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Diego Moores Cancer Center
RECRUITINGLa Jolla, California, 92093, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.